Gene Editing Pioneer Skyrockets Ahead of First Human Trial
- Crispr shares surge close to 200% this year, leading peers
- Company to dose first patient in blood disease trial this year
This article is for subscribers only.
Crispr Therapeutics AG’s stock has soared to repeated record highs, sextupling in value to $3 billion, as analysts have leap-frogged over one another to assign fresh Street-high price targets. This for a company that has yet to hold even a single clinical trial.
Crispr aims to create therapies using the break-through gene editing technology it shares a name with to rid patients of rare blood diseases like beta-thalassemia and sickle cell disease. The excitement and potential of CRISPR/Cas9 has taken Wall Street by storm, helping shares rally close to 200 percent this year.